-+ 0.00%
-+ 0.00%
-+ 0.00%

Rigel Pharmaceuticals pays $70 million upfront for global rights to Arvinas-Pfizer breast cancer drug VEPPANU

PUBT·06/17/2026 20:06:47
Listen to the news
Rigel Pharmaceuticals pays $70 million upfront for global rights to Arvinas-Pfizer breast cancer drug VEPPANU
  • Rigel Pharmaceuticals completed a license deal securing exclusive global rights to develop, manufacture, commercialize VEPPANU (vepdegestrant) worldwide.
  • Transaction closed once Hart-Scott-Rodino review cleared and other closing conditions were met.
  • Rigel paid a one-time upfront payment of USD 70 million to Arvinas and Pfizer.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rigel Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001034842-26-000043), on June 17, 2026, and is solely responsible for the information contained therein.